Treating myoclonic epilepsy in children: State-of-the-art

Pasquale Striano, Vincenzo Belcastro

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Introduction: Myoclonic seizures can be observed in various clinical settings and different epileptic conditions, including some forms of both diopathic and symptomatic epilepsies. Relatively little has been written on treatment of myoclonic seizures. Some old antiepileptic drugs, such as valproate and some benzodiazepines, are widely used but more treatment options exist today for some newer antiepileptic drugs. Nevertheless, patients can be refractory to drug treatment and some drugs may exacerbate or even induce myoclonus. Areas covered: Key safety, tolerability, and efficacy data are presented for different antiepileptic drugs with antimyoclonic effect, alone and/or in combination. Expert opinion: Treatment of myoclonic seizures in children is mainly based on prospective and retrospective studies, with little evidence from randomized clinical trials. Valproate is commonly the first choice alone or in combination with some benzodiazepines or levetiracetam. There is still insufficient evidence for the use of topiramate and zonisamide as monotherapy. Of major importance remains avoidance of medication that may aggravate the seizures. Better understanding of pathophysiologic mechanisms of myoclonic seizures and myoclonic epilepsies could yield great improvement in the treatment and quality of life of patients.

Original languageEnglish
Pages (from-to)1355-1361
Number of pages7
JournalExpert Opinion on Pharmacotherapy
Volume14
Issue number10
DOIs
Publication statusPublished - Jul 2013

Fingerprint

Myoclonic Epilepsy
Seizures
Anticonvulsants
zonisamide
etiracetam
Valproic Acid
Benzodiazepines
Therapeutics
Myoclonus
Expert Testimony
Pharmaceutical Preparations
Epilepsy
Randomized Controlled Trials
Retrospective Studies
Quality of Life
Prospective Studies
Safety

Keywords

  • Antiepileptic drugs
  • Clinical trials
  • Myoclonic seizures
  • Myoclonus
  • Review
  • Therapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Treating myoclonic epilepsy in children : State-of-the-art. / Striano, Pasquale; Belcastro, Vincenzo.

In: Expert Opinion on Pharmacotherapy, Vol. 14, No. 10, 07.2013, p. 1355-1361.

Research output: Contribution to journalArticle

Striano, Pasquale ; Belcastro, Vincenzo. / Treating myoclonic epilepsy in children : State-of-the-art. In: Expert Opinion on Pharmacotherapy. 2013 ; Vol. 14, No. 10. pp. 1355-1361.
@article{08825bea3c8e4f8d9471f8ce42d1a664,
title = "Treating myoclonic epilepsy in children: State-of-the-art",
abstract = "Introduction: Myoclonic seizures can be observed in various clinical settings and different epileptic conditions, including some forms of both diopathic and symptomatic epilepsies. Relatively little has been written on treatment of myoclonic seizures. Some old antiepileptic drugs, such as valproate and some benzodiazepines, are widely used but more treatment options exist today for some newer antiepileptic drugs. Nevertheless, patients can be refractory to drug treatment and some drugs may exacerbate or even induce myoclonus. Areas covered: Key safety, tolerability, and efficacy data are presented for different antiepileptic drugs with antimyoclonic effect, alone and/or in combination. Expert opinion: Treatment of myoclonic seizures in children is mainly based on prospective and retrospective studies, with little evidence from randomized clinical trials. Valproate is commonly the first choice alone or in combination with some benzodiazepines or levetiracetam. There is still insufficient evidence for the use of topiramate and zonisamide as monotherapy. Of major importance remains avoidance of medication that may aggravate the seizures. Better understanding of pathophysiologic mechanisms of myoclonic seizures and myoclonic epilepsies could yield great improvement in the treatment and quality of life of patients.",
keywords = "Antiepileptic drugs, Clinical trials, Myoclonic seizures, Myoclonus, Review, Therapy",
author = "Pasquale Striano and Vincenzo Belcastro",
year = "2013",
month = "7",
doi = "10.1517/14656566.2013.800045",
language = "English",
volume = "14",
pages = "1355--1361",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "10",

}

TY - JOUR

T1 - Treating myoclonic epilepsy in children

T2 - State-of-the-art

AU - Striano, Pasquale

AU - Belcastro, Vincenzo

PY - 2013/7

Y1 - 2013/7

N2 - Introduction: Myoclonic seizures can be observed in various clinical settings and different epileptic conditions, including some forms of both diopathic and symptomatic epilepsies. Relatively little has been written on treatment of myoclonic seizures. Some old antiepileptic drugs, such as valproate and some benzodiazepines, are widely used but more treatment options exist today for some newer antiepileptic drugs. Nevertheless, patients can be refractory to drug treatment and some drugs may exacerbate or even induce myoclonus. Areas covered: Key safety, tolerability, and efficacy data are presented for different antiepileptic drugs with antimyoclonic effect, alone and/or in combination. Expert opinion: Treatment of myoclonic seizures in children is mainly based on prospective and retrospective studies, with little evidence from randomized clinical trials. Valproate is commonly the first choice alone or in combination with some benzodiazepines or levetiracetam. There is still insufficient evidence for the use of topiramate and zonisamide as monotherapy. Of major importance remains avoidance of medication that may aggravate the seizures. Better understanding of pathophysiologic mechanisms of myoclonic seizures and myoclonic epilepsies could yield great improvement in the treatment and quality of life of patients.

AB - Introduction: Myoclonic seizures can be observed in various clinical settings and different epileptic conditions, including some forms of both diopathic and symptomatic epilepsies. Relatively little has been written on treatment of myoclonic seizures. Some old antiepileptic drugs, such as valproate and some benzodiazepines, are widely used but more treatment options exist today for some newer antiepileptic drugs. Nevertheless, patients can be refractory to drug treatment and some drugs may exacerbate or even induce myoclonus. Areas covered: Key safety, tolerability, and efficacy data are presented for different antiepileptic drugs with antimyoclonic effect, alone and/or in combination. Expert opinion: Treatment of myoclonic seizures in children is mainly based on prospective and retrospective studies, with little evidence from randomized clinical trials. Valproate is commonly the first choice alone or in combination with some benzodiazepines or levetiracetam. There is still insufficient evidence for the use of topiramate and zonisamide as monotherapy. Of major importance remains avoidance of medication that may aggravate the seizures. Better understanding of pathophysiologic mechanisms of myoclonic seizures and myoclonic epilepsies could yield great improvement in the treatment and quality of life of patients.

KW - Antiepileptic drugs

KW - Clinical trials

KW - Myoclonic seizures

KW - Myoclonus

KW - Review

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84878857382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878857382&partnerID=8YFLogxK

U2 - 10.1517/14656566.2013.800045

DO - 10.1517/14656566.2013.800045

M3 - Article

C2 - 23668690

AN - SCOPUS:84878857382

VL - 14

SP - 1355

EP - 1361

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 10

ER -